コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 e events (pemphigoid, adrenal insufficiency, liver disorder).
2 ng novel therapeutic targets to treat such a liver disorder.
3 y liver disease (NAFLD) is a complex chronic liver disorder.
4 r to Byler disease, an inherited cholestatic liver disorder.
5 or during an acute or decompensated chronic liver disorder.
6 as patients receiving transplants for other liver disorders.
7 ntial target for therapeutic intervention in liver disorders.
8 ases are likely to become the most prevalent liver disorders.
9 such as fenofibrate, in various cholestatic liver disorders.
10 cts from control rats or patients with other liver disorders.
11 stinal diseases, including human cholestatic liver disorders.
12 is, autoimmune, metabolic or alcohol-related liver disorders.
13 abling symptom accompanying many cholestatic liver disorders.
14 development and adverse outcome of multiple liver disorders.
15 velopment of strategies to treat HBV-induced liver disorders.
16 nist that might hold utility in treatment of liver disorders.
17 le formation in the treatment of cholestatic liver disorders.
18 lth in individuals with gastrointestinal and liver disorders.
19 lly in individuals with gastrointestinal and liver disorders.
20 ns of this frequent disease in patients with liver disorders.
21 Hepatomegaly is a sign of many liver disorders.
22 or preservation of organ function in certain liver disorders.
23 The conference focused on fatty liver disorders.
24 n formulae for the treatment of jaundice and liver disorders, against the cholestasis using the alpha
25 r disease (NAFLD) is the most common chronic liver disorder and is strongly associated with obesity a
26 ions are a characteristic feature of several liver disorders and share similarities with cytoplasmic
32 cribes an increasingly prevalent spectrum of liver disorders associated with obesity and metabolic sy
33 ediction models for newly diagnosed cases of liver disorders by using logistic regression and neural
35 g cholangitis (PSC) is a chronic cholestatic liver disorder characterized by inflammation and fibrosi
36 er disease (NAFLD) encompasses a spectrum of liver disorders characterized by abnormal hepatic fat ac
38 plicated in the pathogenesis of a variety of liver disorders; however, the underlying mechanism remai
39 32-year-old first cousin had a self-limited liver disorder in childhood that resolved at age 9 years
41 tty liver disease (NAFLD) is the most common liver disorder in the United States; however, few data a
42 of posttransplantation diabetes mellitus and liver disorders in HNF1B patients, these findings advoca
43 bodies (MDBs), are characteristic of several liver disorders, including alcoholic and nonalcoholic st
45 e be an ideal cell for in vivo therapies for liver disorders or for use in bioartificial liver device
47 , celiac disease can coexist with autoimmune liver disorders such as autoimmune hepatitis, primary bi
48 nts and has a high probability of developing liver disorders such as fibrosis, cirrhosis, and cancer.
51 bolic diseases linked to insulin resistance, liver disorders such as primary biliary cirrhosis or non
52 towards using ribozymes for the treatment of liver disorders such as viral hepatitis, adenovirus vect
53 ary cirrhosis (PBC) is a chronic cholestatic liver disorder that can progress to cirrhosis, shortenin
55 , still be of importance in multiple chronic liver disorders that display a ductular response such as
56 s an emerging global epidemic causing severe liver disorders, the molecular mechanisms of HCV pathoge
59 2 each in TP53, VHL, and BRCA1), 1 recessive liver disorder with hepatocellular carcinoma (TJP2), and
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。